National prioritisation groups as of 22 December 2020
Country | Emergency use approval granted? | Vaccine candidate | Priority groups |
UK | 2 December 2020 | Pfizer-BioNTech |
|
USA | 11 December 2020 | Pfizer-BioNTech | Phase 1a: Healthcare personnel and long-term care facility residents. Phase 1b: Front-line essential workers and people aged 75 and older (front-line workers, elderly). Phase 1c: People aged 65–74, people aged 16–64 with high-risk conditions, and other essential workers; and (high-risk groups). Phase 2: People aged 16 and older not in phase 143 (rest of adult population). |
Canada | 9 December 2020 | Pfizer-BioNTech | Stage 1: Residents and staff of congregate living settings that provide care for seniors; and (care workers). Stage 2: Healthcare workers not included in the initial roll-out, residents and staff of all other congregate settings (eg, quarters for migrant workers, correctional facilities, homeless shelters) and essential workers44 (healthcare workers). |
Russia | August 2020 | Sputnik-V | The initial vaccination programme was reportedly offered to employees in Moscow aged 18–60 who work in schools and the health service, and social workers45 (geographical focus: school staff, healthcare workers). |
Israel | No | Pfizer-BioNTech | After healthcare workers and first responders, and people aged 60 and older, the next population group to receive the vaccine will be people in high-risk groups46 (healthcare workers, elderly then high-risk groups). |
The table only includes countries that had begun vaccination and have publicly available data as of the 22 December 2020.